Arrowhead Historical Balance Sheet
0HI3 Stock | 18.58 0.05 0.27% |
Trend analysis of Arrowhead Pharmaceuticals Corp balance sheet accounts such as Short Long Term Debt Total of 139.1 M, Other Current Liabilities of 70.2 M or Total Current Liabilities of 127.3 M provides information on Arrowhead Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Arrowhead Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Arrowhead Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Arrowhead Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Arrowhead Pharmaceuticals is a good buy for the upcoming year.
Arrowhead Pharmaceuticals Inventory |
|
Arrowhead |
About Arrowhead Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Arrowhead Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Arrowhead Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Arrowhead Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Arrowhead currently owns. An asset can also be divided into two categories, current and non-current.
Arrowhead Pharmaceuticals Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Arrowhead Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Arrowhead Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Arrowhead Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Arrowhead Pharmaceuticals Corp are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most accounts from Arrowhead Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Arrowhead Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Arrowhead Stock please use our How to Invest in Arrowhead Pharmaceuticals guide.At this time, Arrowhead Pharmaceuticals' Cash is comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 417.8 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 229.4 K in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 81.6M | 115.2M | 132.4M | 139.1M | Total Assets | 691.9M | 765.6M | 880.4M | 924.4M |
Arrowhead Pharmaceuticals balance sheet Correlations
Click cells to compare fundamentals
Arrowhead Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Arrowhead Pharmaceuticals balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 522.5M | 710.1M | 691.9M | 765.6M | 880.4M | 924.4M | |
Other Current Liab | 32.8M | 33.3M | 100.4M | 58.2M | 66.9M | 70.2M | |
Total Current Liabilities | 40.7M | 146.5M | 74.1M | 105.5M | 121.3M | 127.3M | |
Total Stockholder Equity | 461.8M | 408.8M | 106.0M | 271.3M | 312.0M | 327.6M | |
Property Plant And Equipment Net | 47.0M | 66.0M | 168.6M | 335.6M | 385.9M | 405.2M | |
Net Debt | (122.4M) | (158.9M) | (26.4M) | 4.3M | 3.9M | 4.0M | |
Retained Earnings | (503.8M) | (644.7M) | (820.8M) | (1.0B) | (923.4M) | (877.3M) | |
Accounts Payable | 6.8M | 9.5M | 2.9M | 35.9M | 41.2M | 43.3M | |
Cash | 143.6M | 184.4M | 108.0M | 110.9M | 127.5M | 133.9M | |
Non Current Assets Total | 200.1M | 325.6M | 315.5M | 346.0M | 397.9M | 417.8M | |
Non Currrent Assets Other | 265.4K | 272K | 29.1M | 210K | 241.5K | 229.4K | |
Cash And Short Term Investments | 315.5M | 367.8M | 376.4M | 403.6M | 464.2M | 487.4M | |
Net Receivables | 661.4K | 845.7K | 10.3M | 1.4M | 1.6M | 970.9K | |
Common Stock Shares Outstanding | 100.7M | 103.7M | 105.4M | 106.8M | 122.8M | 128.9M | |
Liabilities And Stockholders Equity | 522.5M | 710.1M | 691.9M | 765.6M | 880.4M | 924.4M | |
Inventory | 3.3M | 4.3M | 4.4M | (21.6M) | (19.5M) | (18.5M) | |
Other Current Assets | 6.0M | 6.6M | 27.5M | 15.9M | 18.3M | 19.2M | |
Other Stockholder Equity | 965.4M | 1.1B | 1.2B | 1.3B | 1.5B | 1.6B | |
Total Liab | 60.7M | 301.3M | 586.0M | 478.4M | 550.1M | 577.7M | |
Total Current Assets | 322.4M | 384.6M | 376.4M | 419.5M | 482.4M | 506.6M | |
Accumulated Other Comprehensive Income | 18.4K | (69K) | (136K) | (3.2M) | (2.9M) | (2.8M) | |
Short Term Debt | 1.1M | 4.5M | 5.6M | 10.6M | 12.1M | 12.8M | |
Common Stock | 194.7K | 197K | 106.0M | 200K | 230K | 218.5K | |
Current Deferred Revenue | 19.3M | 111.1M | 74.1M | 866K | 995.9K | 946.1K | |
Non Current Liabilities Total | 20.0M | 154.8M | 511.9M | 372.9M | 428.9M | 450.3M | |
Short Term Investments | 171.9M | 183.4M | 268.4M | 292.7M | 336.6M | 353.5M | |
Intangible Assets | 15.4M | 13.7M | 12.0M | 10.3M | 11.8M | 10.2M | |
Other Liab | 1.9M | 8.7M | 131.5M | 56.0M | 64.3M | 44.0M | |
Net Tangible Assets | 446.4M | 395.2M | 386.6M | 261.1M | 300.2M | 291.5M | |
Capital Surpluse | 582.9M | 664.1M | 965.4M | 1.1B | 1.2B | 831.6M | |
Property Plant Equipment | 47.0M | 66.0M | 168.6M | 335.6M | 385.9M | 405.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Arrowhead Stock Analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.